3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Dermatologic
1
CNS
1
Conditions
Glioblastoma
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Gemcitabine
5
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Leucovorin
3
Irinotecan
3
Erlotinib Hydrochloride
3
Bevacizumab
3
ulixertinib
2
tovorafenib
2
pembrolizumab
2
Trastuzumab
2
Specimen Handling
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
spartalizumab
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
bemcentinib
×
CNS
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts